Feb 22, 2022 · AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for systemic inflammatory conditions, announced positive pivotal Phase 2b results from its trial evaluating B244 in both pruritus (itch) and appearance of atopic dermatitis (eczema). The trial enrolled 547 patients …

Apr 13, 2017 · AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, announced today completion of patient enrollment in the Company’s Phase 2 clinical trial of its lead product candidate, designated B244, to treat individuals with elevated blood pressure. The multicenter, randomized, double …

May 16, 2023 · The peer-reviewed publication describes the significant effects of B244 in 4 weeks across key endpoints in adult patients with atopic dermatitis and associated pruritus (itch) in the largest study of B244 to date. The study demonstrated significant efficacy of B244 across all clinical endpoints, including the improvement of itch, eczema severity, and quality of life […]

Jan 30, 2024 · AOBiome is a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other diseases. Our proprietary product candidates harness a strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria, or AOB, a human commensal with well …

We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,700 patients have been enrolled in our clinical trials since 2016. Regardless of dose, mode of delivery, indication targeted, or age of patients, our bacterial drug candidate B244 has been very well tolerated with an adverse event profile that is equal to […]

Apr 6, 2023 · The newly issued patent covers Composition of Matter for AOBiome’s proprietary strain of Ammonia Oxidizing Bacteria (AOB), along with additional claims pertaining to a variety of related methods including use thereof in changing a composition of a skin microbiome of a subject, inhibiting microbial growth on a subject’s skin, and treating or preventing a skin […]

Sep 20, 2022 · The additional study showed the MoA related to patients’ continued improvement of itch over time as also observed in the Phase 2b study, which saw an increase from 34.0% at 4 weeks to 40.9% itch reduction at 8 weeks. The study further demonstrates the additional longer-term treatment benefits of the AOB’s cellular structure on itch, even when the bacteria is …

Mar 6, 2019 · Data from its First Pediatric Study are Anticipated in the Second Half of 2019 CAMBRIDGE, Mass., March 6, 2019 /PRNewswire/ — AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of therapeutics for dermatological conditions, migraine, hypertension and other systemic …

Jan 5, 2024 · The license is exclusive for the territory of Japan and contains rights for future indications Maruho is responsible for conducting and bearing costs for development in Japan, which will be conducted jointly with AOB Pharma as part of a Global Phase 3 Study for Atopic Dermatitis encompassing Japan, the US, and EU The deal includes […]

The ability to treat moderate to severe itch quickly without needing moderate to severe drugs, which are either expensive or have a risky safety profile, presents B-244 with a unique market opportunity.